PHAR logo

Pharming Group N.V.

PHAR
Healthcare|Biotechnology|NL
$12.29
-0.01 (-0.08%)
DCF Value
$13.58
Tangible Book / Share
$4.05
Graham Number
$0.56
Cash / Share
$2.63
Next Earnings Report
Mar 11, 2027
EPS est. $0.07 · Revenue est. $107.5M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.
Nov 6, 2026 · GlobeNewsWire
Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
Oct 27, 2026 · GlobeNewsWire
Pharming Group announces third quarter 2026 revenues above market expectations
Oct 22, 2026 · GlobeNewsWire
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
Oct 14, 2026 · GlobeNewsWire
Pharming announces CEO transition
Sep 29, 2026 · GlobeNewsWire
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
Sep 25, 2026 · GlobeNewsWire
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
Sep 22, 2026 · GlobeNewsWire
FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.
Sep 11, 2026 · GlobeNewsWire
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
Aug 13, 2026 · GlobeNewsWire

SEC Filings (51)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 20266-KForeign issuer reportDocumentIndex
Oct 27, 20266-KForeign issuer reportDocumentIndex
Oct 22, 20266-KForeign issuer reportDocumentIndex
Oct 14, 20266-KForeign issuer reportDocumentIndex
Sep 29, 20266-KForeign issuer reportDocumentIndex
Sep 25, 20266-KForeign issuer reportDocumentIndex
Sep 22, 20266-KForeign issuer reportDocumentIndex
Sep 11, 20266-KForeign issuer reportDocumentIndex
Aug 13, 20266-KForeign issuer reportDocumentIndex
Jul 30, 20266-KForeign issuer reportDocumentIndex
Jun 4, 20266-KForeign issuer reportDocumentIndex
May 28, 20266-KForeign issuer reportDocumentIndex
May 22, 20266-KForeign issuer reportDocumentIndex
May 7, 20266-KForeign issuer reportDocumentIndex
May 7, 20266-KForeign issuer reportDocumentIndex
Apr 16, 20266-KForeign issuer reportDocumentIndex
Apr 13, 202620-F/AAnnual report (foreign)DocumentIndex
Apr 2, 20266-KForeign issuer reportDocumentIndex
Apr 2, 202620-FAnnual report (foreign)DocumentIndex
Mar 27, 20266-KForeign issuer reportDocumentIndex
Mar 24, 20266-KForeign issuer reportDocumentIndex
Mar 12, 20266-KForeign issuer reportDocumentIndex
Feb 3, 20266-KForeign issuer reportDocumentIndex
Feb 2, 20266-KForeign issuer reportDocumentIndex
Jan 8, 20266-KForeign issuer reportDocumentIndex
Nov 6, 20256-KForeign issuer reportDocumentIndex
Oct 22, 20256-KForeign issuer reportDocumentIndex
Oct 6, 20256-KForeign issuer reportDocumentIndex
Oct 1, 20256-KForeign issuer reportDocumentIndex
Sep 10, 20256-KForeign issuer reportDocumentIndex
Sep 2, 20256-KForeign issuer reportDocumentIndex
Jul 31, 20256-KForeign issuer reportDocumentIndex
Jun 24, 20256-KForeign issuer reportDocumentIndex
Jun 11, 20256-KForeign issuer reportDocumentIndex
May 8, 20256-KForeign issuer reportDocumentIndex
Apr 30, 20256-KForeign issuer reportDocumentIndex
Apr 25, 20256-KForeign issuer reportDocumentIndex
Apr 23, 20256-KForeign issuer reportDocumentIndex
Apr 7, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Apr 3, 20256-KForeign issuer reportDocumentIndex